PH-797804P38 MAP kinase inhibitor, potent and selective CAS# 586379-66-0 |
- SB 203580
Catalog No.:BCC3663
CAS No.:152121-47-6
- BIRB 796 (Doramapimod)
Catalog No.:BCC2535
CAS No.:285983-48-4
- LY2228820
Catalog No.:BCC2528
CAS No.:862507-23-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 586379-66-0 | SDF | Download SDF |
PubChem ID | 22049997 | Appearance | Powder |
Formula | C22H19BrF2N2O3 | M.Wt | 477.3 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 50 mg/mL (104.76 mM; Need ultrasonic) | ||
Chemical Name | 3-[3-bromo-4-[(2,4-difluorophenyl)methoxy]-6-methyl-2-oxopyridin-1-yl]-N,4-dimethylbenzamide | ||
SMILES | CC1=C(C=C(C=C1)C(=O)NC)N2C(=CC(=C(C2=O)Br)OCC3=C(C=C(C=C3)F)F)C | ||
Standard InChIKey | KCAJXIDMCNPGHZ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C22H19BrF2N2O3/c1-12-4-5-14(21(28)26-3)9-18(12)27-13(2)8-19(20(23)22(27)29)30-11-15-6-7-16(24)10-17(15)25/h4-10H,11H2,1-3H3,(H,26,28) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM; 4-fold more selective versus p38β. | |||||
Targets | p38α | |||||
IC50 | 26 nM |
PH-797804 Dilution Calculator
PH-797804 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.0951 mL | 10.4756 mL | 20.9512 mL | 41.9024 mL | 52.378 mL |
5 mM | 0.419 mL | 2.0951 mL | 4.1902 mL | 8.3805 mL | 10.4756 mL |
10 mM | 0.2095 mL | 1.0476 mL | 2.0951 mL | 4.1902 mL | 5.2378 mL |
50 mM | 0.0419 mL | 0.2095 mL | 0.419 mL | 0.838 mL | 1.0476 mL |
100 mM | 0.021 mL | 0.1048 mL | 0.2095 mL | 0.419 mL | 0.5238 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
PH-797804 is a novel, potent, ATP-competitive and reversible inhibitor of human p38 MAP kinase. It specifically inhibits p38α with IC50 value of 26 nM and K(i) value of 5.8 nM.
PH-797804 inhibits LPS induced TNF-α and IL-1β production in monocytes with a concentration-dependently manner. PH-797804 blocks RANKL and M-CSF induced osteoclast formation in primary rat bone marrow cells.
Orally administered PH-797804 suppresses TNF-α level in a dose-dependent manner in LPS induced Lewis rats and also in cynomolgus monkeys. Additionally, PH-797804 has been shown to inhibit chronic inflammation in arthritis models induced by mouse collagen-induced or rat streptococcal cell wall (SCW) extract.
References:
[1] Hope HR1, Anderson GD, Burnette BL, Compton RP, Devraj RV, Hirsch JL, Keith RH, Li X, Mbalaviele G, Messing DM, Saabye MJ,Schindler JF, Selness SR, Stillwell LI, Webb EG, Zhang J, Monahan JB. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation. J Pharmacol Exp Ther. 2009 Dec;331(3):882-95.
- Boc-ON
Catalog No.:BCC2797
CAS No.:58632-95-4
- H- ß-HoGlu-OH.HCl
Catalog No.:BCC3232
CAS No.:58610-41-6
- m-Anisic acid
Catalog No.:BCC9015
CAS No.:586-38-9
- Anagrelide HCl
Catalog No.:BCC2306
CAS No.:58579-51-4
- Saikosaponin B4
Catalog No.:BCN8516
CAS No.:58558-09-1
- Saikosaponin B1
Catalog No.:BCN5917
CAS No.:58558-08-0
- Losmapimod
Catalog No.:BCC5368
CAS No.:585543-15-3
- Confluentin
Catalog No.:BCN5795
CAS No.:585534-03-8
- Schisantherin A
Catalog No.:BCN1024
CAS No.:58546-56-8
- Schisantherin B
Catalog No.:BCN1023
CAS No.:58546-55-7
- Gomisin A
Catalog No.:BCN5794
CAS No.:58546-54-6
- Cucurbitacin IIA
Catalog No.:BCN5019
CAS No.:58546-34-2
- Boc-Cys(Acm)-ONp
Catalog No.:BCC3375
CAS No.:58651-76-6
- 2-C-Methyl-D-erythritol
Catalog No.:BCC8570
CAS No.:58698-37-6
- 3,4-Dichloro-Phe-OH
Catalog No.:BCC2636
CAS No.:587-56-4
- Dihydrokavain
Catalog No.:BCN2677
CAS No.:587-63-3
- H-D-Cha-OH
Catalog No.:BCC2662
CAS No.:58717-02-5
- 16-Oxoprometaphanine
Catalog No.:BCN5797
CAS No.:58738-31-1
- H-D-Ser-OMe.HCl
Catalog No.:BCC3098
CAS No.:5874-57-7
- Licochalcone A
Catalog No.:BCN6332
CAS No.:58749-22-7
- Licochalcone B
Catalog No.:BCN6333
CAS No.:58749-23-8
- Proparacaine HCl
Catalog No.:BCC5073
CAS No.:5875-06-9
- Meranzin hydrate
Catalog No.:BCN5798
CAS No.:5875-49-0
- Haplopine
Catalog No.:BCN3921
CAS No.:5876-17-5
Discovery and characterization of atropisomer PH-797804, a p38 MAP kinase inhibitor, as a clinical drug candidate.[Pubmed:22174080]
ChemMedChem. 2012 Feb 6;7(2):273-80.
PH-797804 ((aS)-3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl}-N,4- dimethylbenzamde) is a diarylpyridinone inhibitor of p38 mitogen-activated protein (MAP) kinase derived from a racemic mixture as the more potent atropisomer (aS), first proposed by molecular modeling and subsequently confirmed by experiments. Due to steric constraints imposed by the pyridinone carbonyl group and the 6- and 6'-methyl substituents of PH-797804, rotation around the connecting bond of the pyridinone and the N-phenyl ring is restricted. Density functional theory predicts a remarkably high rotational energy barrier of >30 kcal mol(-1), corresponding to a half-life of more than one hundred years at room temperature. This gives rise to discrete conformational spaces for the N-phenylpyridinone group, and as a result, two atropic isomers that do not interconvert under ambient conditions. Molecular modeling studies predict that the two isomers should differ in their binding affinity for p38alpha kinase; whereas the atropic S (aS) isomer binds favorably, the opposite aR isomer incurs significant steric interference with p38alpha kinase. The two isomers were subsequently identified and separated by chiral chromatography. IC50 values from p38alpha kinase assays confirm that one atropisomer is >100-fold more potent than the other. It was ultimately confirmed by small-molecule X-ray diffraction that the more potent atropisomer, PH-797804, is the aS isomer of the racemic pair. Extensive pharmacological characterization supports that PH-797804 carries most activity both in vitro and in vivo, and it has a stability profile compatible with oral formulation and delivery options.
Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase.[Pubmed:21641211]
Bioorg Med Chem Lett. 2011 Jul 1;21(13):4066-71.
The synthesis and SAR studies of a novel N-aryl pyridinone class of p38 kinase inhibitors are described. Systematic structural modifications to the HTS lead, 5, led to the identification of (-)-4a as a clinical candidate for the treatment of inflammatory diseases. Additionally, the chiral synthesis and properties of (-)-4a are described.
Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804.[Pubmed:19496616]
Biochemistry. 2009 Jul 14;48(27):6402-11.
PH-797804 is a diarylpyridinone inhibitor of p38alpha mitogen-activated protein (MAP) kinase derived from a racemic mixture as the more potent atropisomer (aS), first proposed by molecular modeling and subsequently confirmed by experiments. On the basis of structural comparison with a different biaryl pyrazole template and supported by dozens of high-resolution crystal structures of p38alpha inhibitor complexes, PH-797804 is predicted to possess a high level of specificity across the broad human kinase genome. We used a structural bioinformatics approach to identify two selectivity elements encoded by the TXXXG sequence motif on the p38alpha kinase hinge: (i) Thr106 that serves as the gatekeeper to the buried hydrophobic pocket occupied by 2,4-difluorophenyl of PH-797804 and (ii) the bidentate hydrogen bonds formed by the pyridinone moiety with the kinase hinge requiring an induced 180 degrees rotation of the Met109-Gly110 peptide bond. The peptide flip occurs in p38alpha kinase due to the critical glycine residue marked by its conformational flexibility. Kinome-wide sequence mining revealed rare presentation of the selectivity motif. Corroboratively, PH-797804 exhibited exceptionally high specificity against MAP kinases and the related kinases. No cross-reactivity was observed in large panels of kinase screens (selectivity ratio of >500-fold). In cellular assays, PH-797804 demonstrated superior potency and selectivity consistent with the biochemical measurements. PH-797804 has met safety criteria in human phase I studies and is under clinical development for several inflammatory conditions. Understanding the rationale for selectivity at the molecular level helps elucidate the biological function and design of specific p38alpha kinase inhibitors.
Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial.[Pubmed:23539534]
Thorax. 2013 Aug;68(8):738-45.
RATIONALE: Chronic obstructive pulmonary disease (COPD) is a common lung disease leading to progressive decline in lung function. Inhibition of release of inflammatory mediators by p38 inhibitors may be a useful treatment for chronic inflammation of the airways thought to underlie the pathogenesis of the disease. OBJECTIVES: To evaluate the efficacy and safety of PH-797804, a potent and selective p38 inhibitor, in adults with moderate to severe COPD (Global Initiative for Chronic Obstructive Lung Disease stage II/III). METHODS: This was a randomised, adaptive design, double-blind, placebo-controlled, parallel-group, multicentre trial. Patients were initially randomised to placebo, 0.5, 3, 6 or 10 mg PH-797804 once daily and treated for 6 weeks following a 2-week run-in. MEASUREMENTS AND MAIN RESULTS: The primary endpoint was change from baseline in trough forced expiratory volume in 1 s (FEV1) compared with placebo after 6 weeks of treatment. Secondary endpoints included other spirometric parameters, transition dyspnoea index, rescue mediation use, high sensitivity C-reactive protein and symptoms. A total of 230 patients were assigned to treatment; placebo (n=45), 0.5 mg (n=20), 3 mg (n=47), 6 mg (n=70) and 10 mg (n=48). PH-797804 showed a statistically significant improvement in trough FEV1 at week 6 compared with placebo of 0.086 litre (95% Bayesian CI 0.008 to 0.164) and 0.093 litre (95% CI 0.018 to 0.166) at 3 and 6 mg PH-797804, respectively. PH-797804 3 mg and 6 mg showed an improvement in the baseline dyspnoea index/transition dyspnoea index total focal score at week 6. PH-797804 was well tolerated at all doses studied. CONCLUSIONS: PH-797804 demonstrated improvements over placebo in lung function parameters and dyspnoea in patients with moderate to severe COPD. TRIALREGNO: NCT00559910.